Pancreatic Cancer Case Finding

In recent years, we have witnessed the first sustained rise in early cancer diagnoses in over a decade, and we are committed to continually exploring innovative ways to build on this positive momentum.

As part of this ongoing effort, NHS England is launching an exciting new pilot initiative aimed at enhancing the early detection of pancreatic cancer through targeted case finding in primary care settings. 

Pancreatic cancer, while the 10th most common cancer in the UK, ranks as the 5th leading cause of cancer-related death in England. It accounts for approximately 3% of all cancer diagnoses, yet it remains one of the most difficult cancers to survive, with only 7.3% of patients living beyond five years after their diagnosis. Research suggests that case-finding programmes could lead to a 2.6% to 4.7% improvement in the diagnosis of pancreatic cancer at earlier, more treatable stages. 

In January, the SWAG Cancer Alliance submitted a proposal to participate in the national case-finding pilot, and we are delighted to announce that our bid was successful. We will be taking part in the first phase of the pilot, which is scheduled to begin in April 2025 and will run for a duration of two years. This marks a significant step forward in our collective efforts to improve early cancer detection and outcomes for patients across the region. 

We are pleased to confirm the involvement of seven Primary Care Networks (PCNs) who will be partnering with us to trial and evaluate the case-finding methodology specifically for pancreatic cancer. These networks will play a crucial role in identifying patients who may benefit from early diagnostic interventions, ultimately helping to increase the chances of early detection and, potentially, better outcomes for those diagnosed. 

As we move forward with this important pilot, we will continue to provide regular updates on its progress and outcomes. Stay tuned for further announcements and thank you for your ongoing support as we work together to make a real difference in the fight against pancreatic cancer.